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Case presentation
A
three-week-old boy with Down syndrome pre-
sented with poor feeding and jaundice. He had
been born at term by normal delivery at home.
The pregnancy had been uneventful and the mother had
declined antenatal testing so the diagnosis of Down
syndrome was made in the postnatal period. The infant
required oxygen at birth and was admitted to the
neonatal unit for a few days after birth. He started to
become jaundiced after discharge. There was no family
history of note and the infant has three siblings who are
healthy. The mother is Rh D positive.
On examination the infant was jaundiced, with neither
hepatosplenomegaly, nor signs of sepsis but had hypoto-
nia typical of Down syndrome. Investigations revealed
unconjugated jaundice with a negative direct antiglobulin
test. A full blood count showed thrombocytopenia with a
platelet count of 6510
9/L, a white cell count of 8.6
10
9/L, neutrophil count of 1.910
9/L and haemoglobin
level of 18.0 g/dL. Blast cells of medium to large size
with cytoplasmic blebs were found on the blood film (see
Fig. 1). Immunophenotyping showed the blasts to have
myeloid markers with expression of CD41 and CD61.
The infant was treated with phototherapy and the
jaundice improved. He was followed up closely with
weekly full blood counts for two months.
Diagnosis
Transient abnormal myelopoiesis (ICD-O 9898/1).
He was reviewed in clinic after three months when he
was found to be well and gaining weight. His full blood
count showed the previously documented thrombopenia
had normalised but neutropenia had persisted: haemo-
globin 11.5 g/dL, white cell count 5.4109/L, platelets
334109/L and neutrophils 1.09109/L. Vacuolated
neutrophils, reactive lymphocytes and the occasional
primitive cell were seen on blood film reflective of a
reactive process. Within a further two months and at an
age of six months his full blood count had normalised
completely confirming that the diagnosis had been
transient abnormal myelopoesis (TAM). He continues
to have monthly full blood counts as 70% of acute
myeloid leukaemia (AML) cases following TAM develop
some form of cytopenia prior to developing an increasing
blast percentage.
Discussion
TAM is the clonal proliferation of myeloid blast cells
which affects an estimated 510% of infants with Down
syndrome and trisomy 21 mosaicism (1). The majorities
of infants with TAM are asymptomatic and picked up
incidentally on routine testing. Most cases of TAM
resolve over the first few months of life, but 1333%
may go on to develop AML within the first four years of
life.
Neonates with Down syndrome are unique in having a
predisposition to transient abnormal myelopoeisis (2).
One of the reasons for this is thought to be that trisomy 21
affects foetal liver haematopoesis causing an increase in
the megakaryocyte-erythroid progenitor frequency with
common myeloid progenitors and a reduction in
the granulocytemonocyte progenitors. Increased clono-
genicity affecting megakaryocyteerythroid progenitors,
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Fig. 1. Photomicrograph of a typical TAM blast cell seen on
a blood ﬁlm (600 oil immersion objective).
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locytes has also been found (3). GATA-1 mutations, a
transcription factor mutation integral to the normal
development of erythroid, megakaryocytic and basophilic
cell lines, have been associated with TAM and AML in
Down syndrome (4). As such, TAM and myeloid leukae-
mia of Down syndrome provides an excellent model for
leukaemogenesis (5).
TAM is difficult to diagnose and is not easily
distinguished from AML. Microscopically, TAM is seen
as an increase in the number of blasts on peripheral blood
film with thrombocytopenia or other cytopenias. There
may be fewer blasts in the marrow than peripheral blood.
Five-year survival after TAM is 85% and event-free
survival 63% (1). The typical clinic picture of a patient
requiring treatment is one of an unwell infant on
intensive care with an oxygen or inotrope requirement
or serious bleed. Often they have hepatomegaly. Factors
associated with early death in TAM include a high white
cell count, increased liver enzymes, failure to normalise
the blood count, ascites, preterm delivery, bleeding
diatheses and failure of spontaneous remission (1).
These events can occur in utero and be a cause of foetal
death. Treatment with low-dose cytarabine in TAM
patients with a high white cell count, thrombocytopenia
or liver dysfunction has been found to have a favourable
effect on five-year event-free survival (1). The dose
chosen is usually 12 mg/kg intravenous or subcutaneous
daily for 37 days (1). The diagnosis of TAM has
prognostic importance as AML patients with a history
of TAM have a better five-year event-free survival than
those without (1).
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